全文获取类型
收费全文 | 59962篇 |
免费 | 5966篇 |
国内免费 | 214篇 |
专业分类
耳鼻咽喉 | 523篇 |
儿科学 | 1657篇 |
妇产科学 | 1063篇 |
基础医学 | 8030篇 |
口腔科学 | 1468篇 |
临床医学 | 6844篇 |
内科学 | 12735篇 |
皮肤病学 | 1000篇 |
神经病学 | 4657篇 |
特种医学 | 2465篇 |
外国民族医学 | 1篇 |
外科学 | 8096篇 |
综合类 | 1353篇 |
一般理论 | 47篇 |
预防医学 | 6367篇 |
眼科学 | 1195篇 |
药学 | 4649篇 |
中国医学 | 137篇 |
肿瘤学 | 3855篇 |
出版年
2022年 | 489篇 |
2021年 | 922篇 |
2020年 | 586篇 |
2019年 | 971篇 |
2018年 | 1102篇 |
2017年 | 870篇 |
2016年 | 985篇 |
2015年 | 1137篇 |
2014年 | 1481篇 |
2013年 | 2056篇 |
2012年 | 3089篇 |
2011年 | 3059篇 |
2010年 | 1773篇 |
2009年 | 1615篇 |
2008年 | 2885篇 |
2007年 | 3119篇 |
2006年 | 2937篇 |
2005年 | 2920篇 |
2004年 | 2623篇 |
2003年 | 2617篇 |
2002年 | 2517篇 |
2001年 | 1675篇 |
2000年 | 1591篇 |
1999年 | 1609篇 |
1998年 | 761篇 |
1997年 | 649篇 |
1996年 | 614篇 |
1995年 | 618篇 |
1994年 | 513篇 |
1993年 | 550篇 |
1992年 | 1270篇 |
1991年 | 1175篇 |
1990年 | 1118篇 |
1989年 | 1081篇 |
1988年 | 1004篇 |
1987年 | 998篇 |
1986年 | 1006篇 |
1985年 | 928篇 |
1984年 | 803篇 |
1983年 | 669篇 |
1982年 | 456篇 |
1981年 | 377篇 |
1980年 | 370篇 |
1979年 | 602篇 |
1978年 | 510篇 |
1977年 | 401篇 |
1976年 | 398篇 |
1974年 | 445篇 |
1973年 | 417篇 |
1972年 | 401篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
991.
Graham G Dark A Hilary Calvert Robert Grimshaw Christopher Poole Ken Swenerton Stan Kaye Robert Coleman Gordon Jayson Tien Le Susan Ellard Marc Trudeau Paul Vasey Marta Hamilton Terri Cameron Emma Barrett Wendy Walsh Lynn McIntosh Elizabeth A Eisenhauer 《Journal of clinical oncology》2005,23(9):1859-1866
PURPOSE: Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan (GI147211), which demonstrated superior levels of activity compared with topotecan in preclinical models. We studied two schedules of OSI-211 in a randomized design in relapsed ovarian cancer to identify the more promising of the two schedules for further study. PATIENTS AND METHODS: Eligible patients had measurable epithelial ovarian, fallopian, or primary peritoneal cancer that was recurrent after one or two prior regimens of chemotherapy. Patients were randomly assigned to receive either arm A (OSI-211 1.8 mg/m(2)/d administered by 30-minute intravenous infusion on days 1, 2, and 3 every 3 weeks) or arm B (OSI-211 2.4 mg/m(2)/d administered by 30-minute intravenous infusion on days 1 and 8 every 3 weeks). The primary outcome measure was objective response, which was confirmed by independent radiologic review, and a pick the winner statistical design was used to identify the schedule most likely to be superior. RESULTS: Eighty-one patients were randomized between October 2000 and September 2001. The hematologic toxic effects were greater on arm A than on arm B (grade 4 neutropenia, 51% v 22%, respectively), as was febrile neutropenia (26% v 2.4%, respectively). Of the 80 eligible patients, eight patients (10%) had objective responses; six responders (15.4%; 95% CI, 6% to 30%) were in arm A and two responders (4.9%; 95% CI, 1% to 17%) were in arm B. CONCLUSION: The OSI-211 daily for 3 days intravenous schedule met the statistical criteria to be declared the winner in terms of objective response. This schedule was also associated with more myelosuppression than the schedule of OSI-211 administered in arm B. 相似文献
992.
Alex Sparreboom Charity D Scripture Vuong Trieu Paul J Williams Tapas De Andrew Yang Bridget Beals William D Figg Michael Hawkins Neil Desai 《Clinical cancer research》2005,11(11):4136-4143
PURPOSE: To compare the preclinical and clinical pharmacokinetic properties of paclitaxel formulated as a Cremophor-free, albumin-bound nanoparticle (ABI-007) and formulated in Cremophor-ethanol (Taxol). EXPERIMENTAL DESIGN: ABI-007 and Taxol were given i.v. to Harlan Sprague-Dawley male rats to determine pharmacokinetic and drug disposition. Paclitaxel pharmacokinetic properties also were assessed in 27 patients with advanced solid tumors who were randomly assigned to treatment with ABI-007 (260 mg/m(2), 30 minutes; n = 14) or Taxol (175 mg/m(2), 3 hours; n = 13), with cycles repeated every 3 weeks. RESULTS: The volume of distribution at steady state and clearance for paclitaxel formulated as Cremophor-free nanoparticle ABI-007 were significantly greater than those for paclitaxel formulated with Cremophor (Taxol) in rats. Fecal excretion was the main elimination pathway with both formulations. Consistent with the preclinical data, paclitaxel clearance and volume of distribution were significantly higher for ABI-007 than for Taxol in humans [21.13 versus 14.76 L/h/m(2) (P = 0.048) and 663.8 versus 433.4 L/m(2) (P = 0.040), respectively]. CONCLUSIONS: Paclitaxel formulated as ABI-007 differs from paclitaxel formulated as Taxol, with a higher plasma clearance and a larger volume of distribution. This finding is consistent with the absence of paclitaxel-sequestering Cremophor micelles after administration of ABI-007. This unique property of ABI-007 could be important for its therapeutic effectiveness. 相似文献
993.
Sofie Gillis Carlos De Wagter Joerg Bohsung Bruce Perrin Peter Williams Ben J Mijnheer 《Radiotherapy and oncology》2005,76(3):340-353
BACKGROUND AND PURPOSE: IMRT necessitates extension of existing inter-centre quality assurance programs due to its increased complexity. We assessed the feasibility of an inter-centre verification method for different IMRT techniques. MATERIALS AND METHODS: Eight European radiotherapy institutions of the QUASIMODO network, have designed an IMRT plan for a horseshoe-shaped PTV surrounding a cylindrical OAR in a simplified pelvic phantom. All centres applied common plan objectives but used their own equipment for planning and delivery. They verified the delivery of this plan according to a common protocol with radiographic film and ionisation chamber measurements. The irradiated films, the results of the ionisation chamber measurements and the computed dose distributions were sent to one analysis centre that compared the measured and computed dose distributions with the gamma method and composite dose-area histograms. RESULTS: 4% (relative to the prescribed dose) and 3mm (distance-to-agreement) were decided feasible gamma criteria. The composite dose-area histograms showed a maximum local deviation of 3.5% in the mean dose of the PTV and 5% in the OAR. Systematic differences could be identified, and in some cases explained. CONCLUSIONS: This multi-centre dosimetric verification study demonstrated both the feasibility of a multi-centre quality assurance network to evaluate any IMRT planning and delivery system combination, as well as the validity of the methodology involved. 相似文献
994.
Hiroya Takeuchi Ken Futamata Arafumi Maeshima Shigemichi Hirose Atsushi Shimada Yoshiki Kawaguchi Jo Tokuyama Koji Osumi Shinya Kishi Takashi Hojo Shiei Kim Norihito Wada Takashi Oishi Yoh Isobe Shunji Ikeuchi Kiyoshi Kubochi Sumio Matsumoto 《Journal of gastrointestinal cancer》2005,36(2):99-104
We report a very rare case of primary gastric small cell carcinoma (GSCC) that was accompanied with gastric tubular adenocarcinoma. A male in his 60s had an elevated tumor with a central ulceration in the middle stomach. The patient underwent a distal gastrectomy with lymph node dissection. The pathological examination showed two separated lesions of the stomach, which contained the components of primary GSCC and primary gastric tubular adenocarcinoma. Immunohistochemical (IHC) examination demonstrated that the tumor cells in the small cell carcinoma stained positive for synaptophysin, chromogranin A, and neural cell adhesion molecule (NCAM). GSCC cells and adenocarcinoma cells independently metastasized to each regional lymph node. Further studies on the biological behavior of individual tumors may allow the development of new treatment strategies for GSCC. 相似文献
995.
Practical applications of snake venom toxins in haemostasis 总被引:8,自引:0,他引:8
Snake venom toxins affecting haemostasis have facilitated extensively the routine assays of haemostatic parameters in the coagulation laboratory. Snake venom thrombin-like enzymes (SVTLE) are used for fibrinogen/fibrinogen breakdown product assay and for the detection of fibrinogen dysfunction. SVTLE are not inhibited by heparin and can thus can be used for assaying antithrombin III and other haemostatic variables in heparin-containing samples. Snake venoms are a rich source of prothrombin activators and these are utilised in prothrombin assays, for studying dysprothrombinaemias and for preparing meizothrombin and non-enzymic forms of prothrombin. Russell's viper (Daboia russelli) venom (RVV) contains toxins which have been used to assay blood clotting factors V, VII, X, platelet factor 3 and, importantly, lupus anticoagulants (LA). Other prothrombin activators (from the taipan, Australian brown snake and saw-scaled viper) have now been used to assay LA. Protein C and activated protein C resistance can be measured by means of RVV and Protac®, a fast acting inhibitor from Southern copperhead snake venom and von Willebrand factor can be studied with botrocetin® from Bothrops jararaca venom. The disintegrins, a large family of Arg-Gly-Asp (RGD)-containing snake venom proteins, show potential for studying platelet glycoprotein receptors, notably, GPIIb/IIIa and Ib. Snake venom toxins affecting haemostasis are also used in the therapeutic setting: Ancrod (from the Malayan pit viper, Calloselasma rhodostoma), in particular, has been used as an anticoagulant to achieve ‘therapeutic defibrination’. Other snake venom proteins show promise in the treatment of a range of haemostatic disorders. 相似文献
996.
Using fMRI to quantify the time dependence of remifentanil analgesia in the human brain. 总被引:3,自引:0,他引:3
To understand and exploit centrally acting drugs requires reliable measures of their time course of action in the human brain. Functional magnetic resonance imaging (fMRI) is able to measure noninvasively, drug-induced changes in task-related brain activity. Here, we have characterized, in a specific region of the brain, the time of onset of action and the half-life of action of a clinically relevant dose of a potent opioid analgesic agent, remifentanil. These times were established from the temporal variation of the amplitude of the blood oxygen level-dependent response in the insular cortex contralateral to a painfully hot thermal stimulus, in volunteers receiving a remifentanil infusion. The insular cortex has repeatedly been reported as activated by noxious thermal stimulation. The times of onset and offset of drug action were each characterized by a half-life for changes in fMRI signal from within the insula. These characteristic times agreed with the observed drug-induced analgesia and previous pharmacokinetic-pharmacodynamic measurements for remifentanil. We have successfully measured, for the first time using fMRI, temporal pharmacological parameters for a CNS-active drug based on its effect on task-related activity in a specific brain region. Comparison of the time course of regional brain activity with pain perception could reveal those regions engaged in drug-induced analgesia. 相似文献
997.
Sharon K Krueger Lisbeth K Siddens Sarah R Martin Zhen Yu Clifford B Pereira Erwin T Cabacungan Ronald N Hines Kristin G Ardlie Judy L Raucy David E Williams 《Drug metabolism and disposition》2004,32(12):1337-1340
A polymorphism for the phase I drug-metabolizing enzyme, flavin-containing monooxygenase isoform 2 (FMO2), encoding either truncated inactive protein, FMO2X472 (FMO2.2A), or full-length active enzyme, FMO2Q472 (FMO2.1), is known and exhibits significant interethnic differences in allelic frequency. FMO2 is the major or sole FMO isoform expressed in the lung of most mammals, including nonhuman primates. To date, FMO2.1 has been found only in African-American and Hispanic populations, rendering individuals with this allele subject to drug metabolism that is potentially different from that of the general population. Approximately 26% of African-Americans (n = 180) possess the FMO2*1 allele. In preliminary studies, we initially estimated that 5% of Hispanics (n = 40) have the FMO2*1 allele, but access to large cohorts of individuals of defined national origin has allowed us to determine the occurrence among Mexican-American and Puerto Rican-American groups. We used allele-specific genotyping to detect FMO2*1 from 632 Hispanic individuals, including 280 individuals of Mexican origin and 327 individuals of Puerto Rican origin. Statistical analysis indicated that results from Mexican (five sample sources) and Puerto Rican (three sample sources) samples were consistent with the hypothesis of homogeneity within each group from different sources. Data were subsequently pooled across sources to test for evidence of a difference in occurrence of FMO2*1 between ethnic groups. There was strong evidence (p = 0.0066) that FMO2*1 is more common among Puerto Ricans (7%) than among individuals of Mexican descent (2%). The overall occurrence of FMO2*1 among Hispanics of all origins is estimated to be between 2 and 7%. 相似文献
998.
999.
1000.
Randle JA Kreder HJ Stephen D Williams J Jaglal S Hu R 《Clinical orthopaedics and related research》2000,(377):217-227
A MEDLINE search from 1980 through 1996 revealed 1845 articles dealing with calcaneal fractures. Six of these articles that compared operative versus nonoperative treatment for displaced calcaneal fractures met the minimum criteria for inclusion in a meta-analysis. A statistical summary of information across the six articles revealed a trend for surgically treated patients to be more likely to return to the same type of work as compared with nonoperatively treated individuals. There also was a trend for nonoperatively treated patients to have a higher risk of experiencing severe foot pain than did operatively treated patients. Unfortunately, none of the other outcomes could be summarized formally across studies using statistical techniques because of variability in reporting across studies. Although the tendency was always for operatively treated patients to have better outcomes (reaching statistical significance in some of the articles), the strength of evidence to recommend operative treatment for displaced intraarticular calcaneal fractures remains weak. A large prospective randomized controlled trial should be able to answer this question. 相似文献